Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Natera, Inc. - Common Stock (NQ:NTRA)

196.91 +1.59 (+0.81%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 14, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Natera, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
20 21 Next >
News headline image
5 Must-Read Analyst Questions From Natera’s Q1 Earnings Call
Natera’s first quarter was marked by robust top-line growth and higher-than-expected sales volumes, but the market responded negatively due to a wider-than-a... 
Via StockStory
Topics Earnings
News headline image
Why Natera (NTRA) Shares Are Plunging Today
What Happened? Shares of genetic testing company Natera (NASDAQ:NTRA). fell 12.2% in the afternoon session after the company reported mixed first-quarter 202... 
Via StockStory
Topics Artificial Intelligence Economy
News headline image
Natera Q1 Earnings Call Highlights ↗
Natera (NASDAQ:NTRA) reported first-quarter 2026 revenue of $697 million, up 39% year over year, as the company delivered more than 1 million total units in a single quarter for the first time. Chief... 
Via MarketBeat
Topics Earnings
News headline image
NTRA Q1 Deep Dive: Robust Volume Growth and Product Expansion Shape Outlook
Genetic testing company Natera (NASDAQ:NTRA). reported Q1 CY2026 results topping the market’s revenue expectations, with sales up 38.8% year on year to $696.... 
Via StockStory
Natera (NTRA) Q1 Revenue Beat Overshadowed by EPS Miss and Operating Losses ↗
Via Chartmill
News headline image
Natera NTRA Q1 2026 Earnings Call Transcript ↗
Natera NTRA Q1 2026 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Natera’s (NASDAQ:NTRA) Q1 CY2026 Sales Top Estimates
Genetic testing company Natera (NASDAQ:NTRA). announced better-than-expected revenue in Q1 CY2026, with sales up 38.8% year on year to $696.6 million. Its GA... 
Via StockStory
News headline image
Natera Reports First Quarter 2026 Financial Results
From Natera, Inc.
Via Business Wire
News headline image
What To Expect From Natera’s (NTRA) Q4 Earnings
Genetic testing company Natera (NASDAQ:NTRA). will be announcing earnings results this Thursday afternoon. Here’s what to expect. Natera beat analysts’ reven... 
Via StockStory
News headline image
Natera to Report its First Quarter Results on May 7, 2026
From Natera, Inc.
Via Business Wire
News headline image
Prospera™ Evidence in Heart and Lung Transplantation Featured Across 17 Presentations at ISHLT
From Natera, Inc.
Via Business Wire
News headline image
Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at ... 
Via StockStory
Topics Artificial Intelligence
News headline image
3 Reasons We’re Fans of Natera (NTRA)
Natera has had an impressive run over the past six months as its shares have beaten the S&P 500 by 6%. The stock now trades at $208.20, marking a 10.5% gain.... 
Via StockStory
Topics Stocks
News headline image
Natera, UFP Technologies, Mettler-Toledo, and Viatris Shares Are Soaring, What You Need To Know
What Happened? A number of stocks jumped in the afternoon session after the reopening of the Strait of Hormuz signaled a cooling of global logistics and ener... 
Via StockStory
Topics Economy Government Stocks
News headline image
1 Cash-Producing Stock to Own for Decades and 2 That Underwhelm
Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it eff... 
Via StockStory
News headline image
Natera Highlights Positive Interim Futility Analysis from Allogene Therapeutics’ MRD-Guided ALPHA3 Trial in Large B-Cell Lymphoma
From Natera, Inc.
Via Business Wire
News headline image
Judge Awards 30% Ongoing Royalty to Natera for its MRD-Related Patents
From Natera, Inc.
Via Business Wire
News headline image
1 of Wall Street’s Favorite Stock with Exciting Potential and 2 We Find Risky
The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these f... 
Via StockStory
News headline image
3 Reasons NTRA Has Explosive Upside Potential
Even during a down period for the markets, Natera has gone against the grain, climbing to $211.23. Its shares have yielded a 22.1% return over the last six m... 
Via StockStory
News headline image
20 Abstracts at AACR Highlight Scale, Innovation and Clinical Impact of Natera’s Oncology Platform
From Natera, Inc.
Via Business Wire
News headline image
SignateraTM MRD Identifies Breast Cancer Patients Who Can Forgo Surgery
From Natera, Inc.
Via Business Wire
News headline image
Elanco, Tandem Diabetes, Fortrea, Natera, and Myriad Genetics Shares Plummet, What You Need To Know
What Happened? A number of stocks fell in the afternoon session after major indices including the S&P 500 and Dow Jones Industrial Average fell sharply as in... 
Via StockStory
Topics Government Stocks
News headline image
Abbott Laboratories Finalizes $21 Billion Acquisition of Exact Sciences, Redefining the Future of Cancer Diagnostics
CHICAGO — In a move that fundamentally reshapes the global diagnostics landscape, Abbott Laboratories (NYSE: ABT) officially completed its $21 billion acquisition of Exact Sciences (NASDAQ: EXAS)... 
Via MarketMinute
Topics Supply Chain
News headline image
1 Unprofitable Stock to Own for Decades and 2 Facing Headwinds
Unprofitable companies can burn through cash quickly, leaving investors exposed if they fail to turn things around. Without a clear path to profitability, th... 
Via StockStory
News headline image
1 Cash-Heavy Stock to Target This Week and 2 We Question
A surplus of cash can mean financial stability, but it can also indicate a reluctance (or inability) to invest in growth. Some of these companies also face c... 
Via StockStory
News headline image
NeoGenomics, Natera, and Amphastar Pharmaceuticals Shares Skyrocket, What You Need To Know
What Happened? A number of stocks jumped in the afternoon session after easing crude oil prices helped lift investor sentiment and reduce inflation worries. ... 
Via StockStory
Topics Economy Stocks
News headline image
This Biotech Stock Surged 75% Last Quarter and Pulled a New $9 Million Investment ↗
Vera Therapeutics develops clinical-stage therapies for serious immunological diseases, with a lead candidate targeting kidney disorders. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This Life Sciences Supplier Has Plunged 50% in a Year, but One Fund Bought Up $28 Million More in Stock ↗
Avantor delivers laboratory materials and specialized services to biopharma, healthcare, and advanced technology clients worldwide. 
Via The Motley Fool
Topics Regulatory Compliance Supply Chain
News headline image
Two Publications Highlight Clinical Utility of Signatera™ in Anal and Rectal Cancers
From Natera, Inc.
Via Business Wire
News headline image
3 Growth Stocks to Add to Your Roster
Growth is oxygen. But when it evaporates, the consequences can be severe - ask anyone who bought Cisco in the Dot-Com Bubble or newer investors who lived thr... 
Via StockStory
< Previous 1 2 3 4 5 6 7 8 9
...
20 21 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.